Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 22, 2024

AstraZeneca targets $80bn revenue by 2030

AstraZeneca has announced an ambitious target to deliver total revenue of $80bn by 2030, an increase from $45.8bn in 2023.  

The company aims to launch approximately 20 new medicines by the end of 2030. Credit: Myriams-Fotos/Pixabay.